home / lobbying / lobbying_activities

lobbying_activities: 2179544

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id filing_uuid filing_type registrant_name registrant_id client_name filing_year filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2179544 fde830ae-0354-45e8-b7a3-283aec7ad0d6 Q3 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2018 third_quarter MMM H.R. 6 - Support for Patients and Communities Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program. S. 3120 - Helping to End Addiction and Lessen Substance Use Disorders Act - Support for policies that help to fight the opioid epidemic with a focus on safe prescriptions in the Medicare program. H.R. 3528/S. 2460 - Every Prescription Conveyed Securely Act - Support for electronic prescribing of opioids to enhance patient safety. S. 2553 - Know the Lowest Price Act of 2018 - Support for the elimination of " gag clauses" in the Medicare Part D program. CMS Regulations related to the Medicare Part D program and Prescription Drug Plans(PDPs). S. 637 - Creating Transparency to Have Prescription Drug Rebates Unlocked - Issues related to the alleged relationship between rebates and drug prices. S. 771 - A Bill to Improve Access to Affordable Prescription Drugs - Issues related to bringing drug prices down including strengthening policies in the Part D coverage gap, couponing and advancing biosimilars. Education activities for Members and staff related to Direct and Indirect Renumeration(DIR)policies. Education activities related to the cross referencing of certain data related to Medicare Parts A, B and D. Trump Administration's Blueprint for lowering the price of prescription medications in the United States and the role that PBMs can play in doing so. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2018-10-02T15:38:20.660000-04:00
Powered by Datasette · Queries took 75.197ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API